The abstract is read at the publisher; the summary is JClub's.
In a phase Ib trial of AML/MDS patients (n = 14), anti-TIM3 sabatolimab plus decitabine expanded cytotoxic NK subsets and enhanced type I IFN signaling.
- Why it matters: AML and MDS can respond to immune checkpoint therapy, but TIM3’s role and how it differs from CTLA4/PD1 in shaping immune activation remains unclear.
- What they did: Patients received sabatolimab with decitabine; TIM3 expression was profiled across NK, myeloid, and T-cell populations, and immune effects were assessed using single-cell RNA/TCR sequencing (n = 6) plus functional coculture assays.
- The result: Responders showed fewer than 1% exhausted bone marrow CD8+ T cells and preferential expansion of small CD8+ clones, with greater cytotoxic CD4+ T-cell expansion; one patient with preexisting CD4+ T-LGLL achieved an outstanding CR lasting 23 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.